EpiPen Class Motion Heads to Trial on Curtailed Antitrust Declare

An EpiPen set during a House Oversight Committee hearing on Capitol Hill addressing the price increase of the company

A consolidated class action lawsuit against the EpiPen, an epinephrine autoinjector used to treat severe allergic reactions, is on trial – albeit on the basis of a shortened antitrust claim.

District Judge Daniel Crabtree in June threw back lawsuits under the Racketeer Influenced and Corrupt Organizations Act and some of the antitrust charges against Mylan Pharmaceuticals for selling the EpiPen, a pen-like device used to treat anaphylaxis, a potentially fatal disease that is caused by food allergies and insect bites.


Please enter your comment!
Please enter your name here